FDA Withdraws Approval for 12 Drug Applications
January 15, 2025
January 15, 2025
WASHINGTON, Jan. 15 (TNSFR) -- The Food and Drug Administration (FDA) has announced the withdrawal of approval for 12 new drug applications (NDAs) after applicants confirmed that these products are no longer marketed.
The decision, effective February 14, 2025, affects widely known drugs such as Diamox IV by Teva, Tarceva by OSI Pharmaceuticals, and Atripla by Gilead Sciences.
The manufacturers requested the withdrawals and waived their rights to a hearing under FDA reg . . .
The decision, effective February 14, 2025, affects widely known drugs such as Diamox IV by Teva, Tarceva by OSI Pharmaceuticals, and Atripla by Gilead Sciences.
The manufacturers requested the withdrawals and waived their rights to a hearing under FDA reg . . .